Avecia clears regulatory hurdles for biotech manufacturing
This article was originally published in Scrip
The privately owned UK contract manufacturer Avecia Biologics has received a manufacturer's licence from the UK regulatory authority, the MHRA, adding to its first successful US FDA pre-approval inspection, which it underwent earlier this year.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.